Biomarker-supported testing for preclinical and prodromal Alzheimer’s disease (AD) finds its way into clinical practice. Professional attitudes and practices regarding disclosure and ethical issues are controversial in many countries.
Objectives:
Against this background, the objective was to survey the actual practice and the attitudes of physicians in German hospitals and memory clinics in order to explore possible practical insecurities and ethical concerns.
Methods:
A detailed survey with 37 items was conducted among medical professionals at German hospitals and memory clinics (n = 108). Analyses were performed using SPSS 21.0 (IBM). Findings were based on frequency and percentage distribution.
Results:
Nearly half of the respondents stated that persons with mild cognitive impairment and pathological cerebrospinal fluid biomarkers were informed they had or would soon develop AD. While 81% acknowledged a ‘right not to know’, 75% said that results were always communicated. A majority agreed there was a benefit of prediction or later life planning [end-of-life, financial, family, housing (73–75%)] but also expected high psychological stress (82%) and self-stigmatization (70%) for those tested.
Conclusions:
There is considerable heterogeneity and insecurity regarding prediction and early detection in the context of AD in Germany. Information of professionals and standardization of professional testing and disclosure practices are needed.
DonovanNJ, AmariglioRE, ZollerAS, RudelRK, Gomez-IslaT, BlackerD, HymanBT, LocascioJJ, JohnsonKA, SperlingR (2014) Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry22, 1642–1651.
5.
JessenF, AmariglioRE, van BoxtelM, BretelerM, CeccaldiM, ChetelatG, DuboisB, DufouilC, EllisKA, Van der FlierWM (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
6.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
7.
FiandacaMS, MapstoneME, CheemaAK, FederoffHJ (2014) The critical need for defining preclinical biomarkers in Alzheimer’s disease. Alzheimers Dement10, S196–S212.
8.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
9.
DuboisB, FeldmanHH, JacovaC, CummingsJL, DeKoskyST, Barberger-GateauP, DelacourteA, FrisonniG, FoxNC, GalaskoD, GauthierS, HampelH, JichaGA, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SarazinM, De SouzaLC, SternY, VisserPJ, ScheltensP (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol9, 1118–1127.
10.
MattssonN, AndreassonU, PerssonS, CarrilloMC, CollinsS, ChalbotS, CutlerN, Dufour-RainfrayD, FaganAM, HeegaardNHH, Robin HsiungG-Y, HymanB, IqbalK, LachnoDR, LleóA, LewczukP, MolinuevoJL, ParchiP, RegeniterA, RissmanR, RosenmannH, SancesarioG, SchröderJ, ShawLM, TeunissenCE, TrojanowskiJQ, VandersticheleH, VandijckM, VerbeekMM, ZetterbergH, BlennowK, KäserSA (2013) CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement9, 251–261.
11.
CarrilloMC, BlennowK, SoaresH, LewczukP, MattssonN, OberoiP, UmekR, VandijckM, SalamoneS, BittnerT, ShawLM, StephensonD, BainL, ZetterbergH (2013) Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: An update from the Alzheimer’s Association Global Biomarkers Consortium. Alzheimers Dement9, 137–140.
RobertsJS, KarlawishJH, UhlmannWR, PetersenRC, GreenRC (2010) Mild cognitive impairment in clinical care: A survey of American Academy of Neurology members. Neurology75, 425–431.
14.
BierJC, VerschraegenJ, VandenbergheR, GuillaumeB, PicardG, OtteG, MormontE, GillesC, SegersK, SiebenA, ThieryE, VenturaM, De DeynP, DeryckO, VersijptJ, SalmonE, EngelborghsS, IvanoiuA (2015) Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: A BeDeCo survey. Acta Neurol Belg115, 547–555.
15.
BocchettaM, GalluzziS, KehoePG, AgueraE, BernabeiR, BullockR, CeccaldiM, DartiguesJ-F, de MendonçaA, DidicM, EriksdotterM, FélicianO, FrölichL, GertzH-J, HallikainenM, HasselbalchSG, HausnerL, HeuserI, JessenF, JonesRW, KurzA, LawlorB, LleoA, Martinez-LageP, MecocciP, MehrabianS, MonschA, NobiliF, NordbergA, RikkertMO, OrgogozoJM, PasquierF, PetersO, SalmonE, Sánchez-CastellanoC, SantanaI, SarazinM, TraykovL, TsolakiM, VisserPJ, WallinÅK, WilcockG, WilkinsonD, WolfH, YenerG, ZekryD, FrisoniGB (2015) The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimers Dement11, 195–206.
WilliamsSJ, HiggsP, KatzS (2012) Neuroculture, active ageing and the “older brain”: Problems, promises, and prospects. Sociol Health Illn34, 64–78.
18.
SchicktanzS, SchwedaM, BallengerJF, FoxPJ, HalpernJ, KramerJH, MiccoG, PostSG, ThompsonC, KnightRT, JagustWJ (2014) Before it is too late: Professional responsibilities in late-onset Alzheimer’s research and pre-symptomatic prediction. Front Hum Neurosci8, 921.
19.
AlzheimerEurope (2016) Discussion paper on ethical issues linked to the changing definitions/use of terms related to Alzheimer’s disease, Alzheimer Europe, Luxembourg.
20.
DeuschlG, Maier Wet al. (2016) S3-Leitlinie Demenzen. 2016. In: Deutsche Gesellschaft für Neurologie (eds.) Leitlinien für Diagnostik und Therapie in der Neurologie. http://www.dgn.org/leitlinien, Accessed August 24, 2017.
21.
MacLeodR, TibbenA, FrontaliM, Evers-KieboomsG, JonesA, Martinez-DescalesA, RoosRA (2013) Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet83, 221–231.
22.
DuboisB, PadovaniA, ScheltensP, RossiA, Dell’AgnelloG (2016) Timely diagnosis for Alzheimer’s disease: A literature review on benefits and challenges. J Alzheimers Dis49, 617–631.
23.
GoldmanJS, HahnSE, CataniaJW, LaRusse-EckertS, ButsonMB, RumbaughM, StreckerMN, RobertsS, BurkeW, MayeuxR, BirdT (2011) Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med13, 597–605.
24.
GrillJD, ApostolovaLG, BullainS, BurnsJM, CoxCG, DickM, HartleyD, KawasC, KremenS, LinglerJ, LopezOL, MapstoneM, PierceA, RabinoviciG, RobertsJS, SajjadiSA, TengE, KarlawishJ (2017) Communicating mild cognitive impairment diagnoses with and without amyloid imaging. Alzheimers Res Ther9, 35.
25.
MitchellT, WoodwardM, HiroseY (2008) A survey of attitudes of clinicians towards the diagnosis and treatment of mild cognitive impairment in Australia and New Zealand. Int Psychogeriatr20, 77–85.
26.
LimYY, MaruffP, GetterC, SnyderPJ (2016) Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. Alzheimers Dement12, 454–458.
27.
BurnsJM, JohnsonDK, LiebmannEP, BothwellRJ, MorrisJK, VidoniED (2017) Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement13, 1024–1030.
28.
WiklerEM, BlendonRJ, BensonJM (2013) Would you want to know? Public attitudes on early diagnostic testing for Alzheimer’s disease. Alzheimers Res Ther5, 43.
29.
MühlbacherA, JohnsonFR, YangJ-C, HappichM, BelgerM (2016) Do you want to hear the bad news? The value of diagnostic tests for Alzheimer’s disease. Value Health19, 66–74.
30.
GooblarJ, RoeCM, SelsorNJ, GabelMJ, MorrisJC (2015) Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol72, 1484–1490.
31.
FowlerNR, FrameA, PerkinsAJ, GaoS, WatsonDP, MonahanP, BoustaniMA (2015) Traits of patients who screen positive for dementia and refuse diagnostic assessment. Alzheimers Dement1, 236–241.
32.
JacksonTA, NaqviSH, SheehanB (2013) Screening for dementia in general hospital inpatients: A systematic review and meta-analysis of available instruments. Age Ageing42, 689–695.
33.
TurnbullQ, WolfAM, HolroydS (2003) Attitudes of elderly subjects toward “truth telling” for the diagnosis of Alzheimer’s disease. J Geriatr Psychiatry Neurol16, 90–93.
34.
PierceS, LamersC, SalisburyK (2016) Knowingly not wanting to know: Discourses of people diagnosed with mild cognitive impairment. Dementia15, 1246–1259.
35.
DowningA, YaariR, BallD, SelzlerK, DevousMSr (2016) Bridging the gap between research and clinical practice in asymptomatic Alzheimer’s disease. J Prev Alzheimers Dis3, 30–42.
36.
SancesarioGM, TonioloS, ChiasseriniD, Di SantoSG, ZegeerJ, BernardiG, MusiccoM, CaltagironeC, ParnettiL, BernardiniS (2017) The clinical use of cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: The Italian selfie. J Alzheimers Dis55, 1659–1666.
37.
SchmidhuberM, BergemannL, FrewerA (2017) Ethical dimensions of international dementia plans. New strategies for human rights. Königshausen & Neumann, Würzburg.
